I Gause-Nilsson
Overview
Explore the profile of I Gause-Nilsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leiter L, Cefalu W, de Bruin T, Xu J, Parikh S, Johnsson E, et al.
Diabetes Obes Metab
. 2016 Mar;
18(8):766-74.
PMID: 27009868
Aim: To evaluate the long-term efficacy, safety and tolerability of dapagliflozin versus placebo added to usual care in patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Methods:...
2.
Heerspink H, Johnsson E, Gause-Nilsson I, Cain V, Sjostrom C
Diabetes Obes Metab
. 2016 Mar;
18(6):590-7.
PMID: 26936519
Aims: To characterize the effect of dapagliflozin on albuminuria and estimated glomerular filtration rate (eGFR) and to determine whether effects on albuminuria were mediated through changes in glycated haemoblogin (HbA1c),...
3.
Lambers Heerspink H, Johnsson E, Gause-Nilsson I, Sjostrom C
Diabetologia
. 2015 Sep;
58(12):2901.
PMID: 26404064
No abstract available.
4.
Steen B, Gause-Nilsson I, Bosaeus I, Alpsten M
Asia Pac J Clin Nutr
. 2014 Jan;
4(1):55-6.
PMID: 24394251
Within the gerontological and geriatric population studies in Gothenburg, Sweden, body composition studies have been performed with a four-compartment model (using whole-body potassium 40 counting and dilution of isotope labelled...
5.
Samuelsson O, Attman P, Gause-Nilsson I, Svensson M, Alaupovic P
PPAR Res
. 2013 Apr;
2013:391628.
PMID: 23606826
Chronic kidney disease (CKD) is characterised by specific lipoprotein abnormalities and insulin resistance. Dual activation of the peroxisome proliferators-activated receptors (PPAR) α and γ can significantly improve insulin sensitivity. The...
6.
Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I, et al.
Int J Clin Pract
. 2011 Oct;
65(12):1230-9.
PMID: 21977965
Objective: Therapeutic options are limited for diabetes patients with renal disease. This report presents 52-week results from a study assessing the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2...
7.
Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I
Diabetes Obes Metab
. 2011 Feb;
13(6):523-32.
PMID: 21332627
Aim: To evaluate the efficacy and safety of saxagliptin vs. placebo in patients with type 2 diabetes mellitus (T2DM) and renal impairment. Methods: In this multicentre, randomized, parallel-group, double-blind, placebo-controlled...
8.
Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I
Int J Clin Pract
. 2010 Sep;
64(12):1619-31.
PMID: 20846286
Aim: To assess the efficacy and safety of saxagliptin vs. glipizide as add-on therapy to metformin in patients with type 2 diabetes mellitus and inadequate glycaemic control on metformin alone....
9.
Gause-Nilsson I, Gherman S, Kumar Dey D, Kennerfalk A, Steen B
Acta Diabetol
. 2007 Jan;
43(4):120-6.
PMID: 17211562
The prevalence of the metabolic syndrome in different elderly European populations has not been well studied. The aim of this study was to measure the prevalence of metabolic syndrome, as...
10.
Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, Stender S, et al.
Diabetologia
. 2005 Jul;
48(9):1716-25.
PMID: 16001233
Aims/hypothesis: Insulin resistance is associated with abnormalities in lipid and glucose metabolism, which are major components of metabolic syndrome and risk factors for vascular disease. This study examined the effect...